FEMSelect Partners with Elidah to Enhance Women's Health Innovations for Incontinence

FEMSelect Expands Women's Health Portfolio with Elidah

In a significant move towards empowering women's health solutions, FEMSelect, a pioneering women-led company, has announced its strategic partnership with Elidah, known for its clinically proven Elitone® device. This partnership is aimed at tackling the incontinence market, providing innovative solutions for millions of women experiencing this common yet overlooked condition.

Founded with a mission to enhance women’s pelvic health, FEMSelect joins forces with Elidah to broaden its women's health offerings. This collaboration allows FEMSelect to distribute Elitone®, an FDA-cleared medical device designed to treat urinary incontinence at home. Urinary incontinence impacts nearly one in three women globally, yet remains underreported and stigmatized.

Elitone® works by administering small electrical signals to the muscles and nerves responsible for pelvic control, promoting strength and coordination. With just 20 minutes of use daily for six weeks, women can significantly reduce unintended leaks. This development aligns seamlessly with FEMSelect’s flagship product, EnPlace®, which has transformed the treatment landscape for pelvic organ prolapse through minimally invasive techniques.

CEO Sasha Schrode expressed enthusiasm over this collaboration, stating, "Elitone® is a breakthrough addition to our portfolio—science-backed, patient-friendly, and filling a substantial gap in women's health needs. Together with Elidah, we aim to deliver life-changing therapies to women across the globe."

By incorporating both treatments for pelvic organ prolapse and urinary incontinence, FEMSelect further solidifies its commitment to comprehensive women’s health care. This partnership is not only an expansion of their product line but also a commitment to equipping healthcare providers with effective solutions that address long-standing women’s health issues.

The collaboration is particularly timely as FEMSelect has been ramping up its growth strategies, following a successful Series B financing round earlier this year and relocating its U.S. headquarters. The company is also actively expanding its commercial team, focusing on raising awareness among both healthcare providers and patients about their innovative solutions.

Elidah, the co-partner in this venture, is a women-led medical device firm dedicated to offering non-invasive options for pelvic health. Its flagship product, Elitone®, is a pioneer in the domain of treating stress urinary incontinence utilizing neuromuscular stimulation.

As FEMSelect works towards creating a robust portfolio of solutions for women, this partnership stands as a testament to their mission of addressing prevalent yet often neglected health conditions. With Elitone® added to their offerings, FEMSelect is set to make significant strides in improving the quality of life for countless women worldwide.

In conclusion, FEMSelect's partnership with Elidah and its commitment to developing effective healthcare solutions reflects a growing recognition of the importance of addressing women’s health issues with sensitivity and innovation. As more women gain access to these transformative technologies, the potential to enhance their everyday lives continues to grow exponentially.